▲ Peaking
Business
Merck’s TROP2 ADC extends survival in pivotal gastroesophageal cancer trial
Merck’s sac-TMT TROP2 antibody-drug conjugate meets its primary overall survival endpoint in a pivotal Phase 3 trial for third-line or later gastroesophageal adenocarcinoma.